Compare IDEXX Laboratories, Inc. (IDXX) vs Rambus Inc. Common Stock (RMBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Rambus Inc. Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $532.96 (market cap $41.68B), while Rambus Inc. Common Stock trades at $88.1 (market cap $9.99B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.2× Rambus Inc. Common Stock's market cap, and IDEXX Laboratories, Inc. is more actively traded (824,427 versus 1,884,427). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and Rambus Inc. Common Stock for 0 Days on average.
| IDXX | RMBS | |
|---|---|---|
Market Cap | $41.68B | $9.99B |
Volume | 824,427 | 1,884,427 |
Sector | Health | Technology |
52-Week High | $766.68 | $170.66 |
52-Week Low | $504.70 | $79.73 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $42.58B | $9.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $520.31, down 0.69% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.27 versus $3.94, maintaining a 3-quarter beat streak. Revenue growth accelerated to $4.3B in 2025 with robust 25.03% net margins and exceptional 74.21% ROE. Recent acquisitions like CoVetAI expand veterinary workflow capabilities while management reaffirmed long-term growth targets at the Morgan Stanley Healthcare Conference.
Wall Street maintains bullish sentiment with 56.5% buy ratings and $665 consensus target implying 28% upside. Strong profitability and diagnostic innovation pipeline support growth, though elevated P/E of 37.2 and recent insider selling pose valuation concerns. Key risks include FX headwinds, weaker U.S. vet visits, and competitive pressures in veterinary diagnostics.
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →
